Meloxicam SBEβCD Inclusion Complex for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief, which is exacerbated by inadequate response to prior migraine treatments.
Innovation Solution
A dosage form comprising an inclusion complex of meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and a bicarbonate, such as sodium bicarbonate, is administered orally or intravenously to enhance solubility and bioavailability, combined with rizatriptan for rapid and sustained pain relief in migraine treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If meloxicam is administered in conventional dosage forms, then the drug can be delivered to patients, but its poor aqueous solubility reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to complex with meloxicam, forming water-soluble inclusion complexes that enhance bioavailability and accelerate absorption, directly resolving the solubility-bioavailability contradiction
Solution Approach 2:
The patent modifies the chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins, changing its solubility characteristics from poor to good, thereby improving bioavailability and absorption rate while maintaining therapeutic efficacy
2Productivity
If conventional migraine treatments are used, then treatment can be provided, but patients with inadequate response experience slow and insufficient pain relief
Solution Approach 1:
The patent combines meloxicam with rizatriptan in a single dosage form, creating a synergistic therapeutic effect that provides both anti-inflammatory and anti-migraine actions, resulting in faster and more adequate pain relief for treatment-resistant patients
Solution Approach 2:
The patent creates a composite pharmaceutical formulation containing multiple active ingredients (meloxicam, rizatriptan, and cyclodextrins) that work together to provide enhanced and accelerated pain relief compared to conventional single-agent treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases the bioavailability and absorption rate of meloxicam, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in patients with inadequate responses to prior therapies.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Disclosed herein are formulations for an inclusion complex of cyclodextrin and meloxicam with bicarbonate and methods of use thereof
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.